Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
DavidAPalma	B-authors

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HanboChen	B-authors

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HoudaBahig	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Centre	O
Hospitalier	O
de	O
l'Université	O
de	O
Montréal	O
1051	O
Sanguinet	O
Street	O
H2X	O
3E4	O
Montreal	O
Quebec	O
Canada	O
StewartGaede	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
StephenHarrow	B-authors

1053	O
Great	O
Western	O
Road	O
G12	O
0YN	O
Glasgow	O
UK	O
JoannaMLaba	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
XMelody	B-authors
Qu	I-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
GeorgeBRodrigues	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
BrianPYaremko	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
EdwardYu	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
AlexanderVLouie	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Sunnybrook	O
Cancer	O
Centre	O
2075	O
Bayview	O
Avenue	O
M4N	O
3M5	O
Toronto	O
Ontario	O
Canada	O
InderdeepDhaliwal	B-authors
Department	O
of	O
Respirology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
ChristopherJRyerson	B-authors
Department	O
of	O
Medicine	O

Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HanboChen	B-authors

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HoudaBahig	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Centre	O
Hospitalier	O
de	O
l'Université	O
de	O
Montréal	O
1051	O
Sanguinet	O
Street	O
H2X	O
3E4	O
Montreal	O
Quebec	O
Canada	O
StewartGaede	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
StephenHarrow	B-authors

1053	O
Great	O
Western	O
Road	O
G12	O
0YN	O
Glasgow	O
UK	O
JoannaMLaba	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
XMelody	B-authors
Qu	I-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
GeorgeBRodrigues	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
BrianPYaremko	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
EdwardYu	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
AlexanderVLouie	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Sunnybrook	O
Cancer	O
Centre	O
2075	O
Bayview	O
Avenue	O
M4N	O
3M5	O
Toronto	O
Ontario	O
Canada	O
InderdeepDhaliwal	B-authors
Department	O
of	O
Respirology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
ChristopherJRyerson	B-authors
Department	O
of	O
Medicine	O

Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HanboChen	B-authors

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
HoudaBahig	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Centre	O
Hospitalier	O
de	O
l'Université	O
de	O
Montréal	O
1051	O
Sanguinet	O
Street	O
H2X	O
3E4	O
Montreal	O
Quebec	O
Canada	O
StewartGaede	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
StephenHarrow	B-authors

1053	O
Great	O
Western	O
Road	O
G12	O
0YN	O
Glasgow	O
UK	O
JoannaMLaba	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
XMelody	B-authors
Qu	I-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
GeorgeBRodrigues	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
BrianPYaremko	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
EdwardYu	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
AlexanderVLouie	B-authors

Department	O
of	O
Radiation	O
Oncology	O
,	O
Sunnybrook	O
Cancer	O
Centre	O
2075	O
Bayview	O
Avenue	O
M4N	O
3M5	O
Toronto	O
Ontario	O
Canada	O
InderdeepDhaliwal	B-authors
Department	O
of	O
Respirology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
ChristopherJRyerson	B-authors
Department	O
of	O
Medicine	O

Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
DavidAPalma	B-authors
david.palma@lhsc.on.ca	O

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
DavidAPalma	B-authors
David	B-authors
A	I-authors
Palma	I-authors
david.palma@lhsc.on.ca	O
0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

0000	O
-	O
0002	O
-	O
9542	O
-	O
0627	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
1051	O
Sanguinet	O
Street	O
H2X	O
3E4	O
Montreal	O
Quebec	O
Canada	O
StewartGaede	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

UK	O
1053	O
Great	O
Western	O
Road	O
G12	O
0YN	O
Glasgow	O
UK	O
JoannaMLaba	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
XMelody	B-authors
Qu	I-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
GeorgeBRodrigues	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
BrianPYaremko	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
EdwardYu	B-authors
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O
Canada	O
Department	O
of	O
Oncology	O
Western	O
University	O
1151	O
Richmond	O
Street	O
N6A	O
3K7	O
London	O
Ontario	O

Canada	O
2775	O
Laurel	O
Street	O
,	O
British	O
Columbia	O
V5Z	O
1M9	O
Vancouver	O
Canada	O
Assessment	O
of	O
precision	O
irradiation	O
in	O
early	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
interstitial	O
lung	O
disease	O
(	O
ASPIRE	O
-	O
ILD	O
)	O
:	O
study	B-study_type
protocol	I-study_type
for	I-study_type
a	I-study_type
phase	I-study_type
II	I-study_type
trial	I-study_type
10.1186	O
/	O
s12885	O
-	O
019	O
-	O
6392	O
-	O
8	O
Received	O
:	O
12	O
July	O
2019	O
Accepted	O
:	O
21	O
November	O
2019	O

Non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
is	O
the	O
leading	O
cause	O
of	O
cancer	O
death	O
in	O
men	O
and	O
women	O
worldwide	O
.	O
Approximately	O
20	O
%	O
of	O
NSCLC	O
patients	O
present	O
with	O
early	O
stage	O
disease	O
(	O
T1	O
N0	O
or	O
T2	O
N0	O
)	O
,	O
defined	O
as	O
tumors	O
up	O
to	O
5	O
cm	O
in	O
size	O
,	O
without	O
nodal	O
or	O
distant	O
metastases	O
.	O
For	O
such	O
patients	O
,	O
surgical	O
resection	O
has	O
been	O
considered	O
the	O
standard	O
of	O
care	O
;	O
however	O
,	O
many	O
patients	O
are	O
ineligible	O
for	O
surgery	O
because	O
of	O
co	O
-	O
morbid	O
conditions	O
.	O

Historically	O
,	O
alternatives	O
to	O
surgery	O
have	O
proven	O
unsatisfactory	O
.	O
Most	O
patients	O
who	O
were	O
not	O
candidates	O
for	O
surgery	O
were	O
treated	O
with	O
conventional	O
radiotherapy	O
,	O
delivered	O
as	O
doses	O
of	O
50	O
-	O
60	O
Gy	O
in	O
4	O
-	O
6	O
weeks	O
,	O
with	O
relatively	O
rudimentary	O
tumor	O
targeting	O
techniques	O
.	O
Conventional	O
radiotherapy	O
was	O
associated	O
with	O
high	O
rates	O
of	O
local	O
recurrence	O
,	O
often	O
30	O
-	O
40	O
%	O
or	O
higher	O
,	O
with	O
only	O
a	O
minor	O
improvement	O
in	O
long	O
-	O
term	O
survival	O
compared	O
to	O
observation	O
alone	O
[	O
1,2	O
]	O
.	O

Stereotactic	O
ablative	O
radiotherapy	O
(	O
SABR	O
)	O
is	O
a	O
newer	O
radiotherapy	O
approach	O
which	O
uses	O
modern	O
radiotherapy	O
planning	O
and	O
targeting	O
technologies	O
to	O
precisely	O
deliver	O
larger	O
,	O
ablative	O
doses	O
of	O
radiotherapy	O
(	O
up	O
to	O
60	O
Gy	O
in	O
3	O
-	O
8	O
fractions	O
)	O
.	O
SABR	O
has	O
been	O
associated	O
with	O
high	O
rates	O
of	O
local	O
control	O
,	O
with	O
many	O
studies	O
reporting	O
3-year	O
local	O
control	O
of	O
approximately	O
90	O
%	O
after	O
SABR	O
,	O
comparable	O
to	O
results	O
obtained	O
with	O
anatomic	O
lobectomy	O
[	O
3	O
]	O
.	O
Because	O
of	O
these	O
promising	O
outcomes	O
,	O
randomized	O
trials	O
are	O
currently	O
comparing	O
SABR	O
vs.	O
surgery	O
as	O
first	O
-	O
line	O
treatment	O
for	O
early	O
-	O
stage	O
NSCLC	O
(	O
ES	O
-	O
NSCLC	O
)	O
.	O

A	O
major	O
advantage	O
of	O
SABR	O
is	O
that	O
in	O
general	O
,	O
the	O
toxicity	O
profile	O
is	O
very	O
favorable	O
,	O
even	O
in	O
patients	O
with	O
substantial	O
co	O
-	O
morbid	O
conditions	O
.	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(	O
RTOG	O
)	O
0236	O
,	O
a	O
North	O
American	O
phase	O
II	O
trial	O
assessing	O
outcomes	O
with	O
SABR	O
for	O
ES	O
-	O
NSCLC	O
in	O
patients	O
who	O
were	O
unfit	O
for	O
surgery	O
,	O
demonstrated	O
a	O
risk	O
of	O
protocol	O
-	O
specified	O
Grade	O
3	O
and	O
4	O
toxicities	O
of	O
13	O
and	O
4	O
%	O
respectively	O
,	O
with	O
no	O
grade	O
5	O
toxicities	O
[	O
4	O
]	O
.	O
Based	O
on	O
a	O
large	O
meta	O
-	O
analysis	O
,	O
the	O
risk	O
of	O
treatment	O
related	O
death	O
after	O
SABR	O
is	O
estimated	O
at	O
<	O
1	O
%	O
.	O
By	O
comparison	O
,	O
after	O
anatomic	O
lobectomy	O
,	O
toxicity	O
rates	O
appear	O
higher	O
:	O
with	O
Grade	O
3	O
or	O
4	O
toxicity	O
often	O
approaching	O
50	O
%	O
,	O
and	O
30-day	O
mortality	O
rates	O
of	O
4	O
-	O
6	O
%	O
based	O
on	O
Medicare	O
data	O
,	O
although	O
this	O
latter	O
risk	O
is	O
lower	O
at	O
specialized	O
highvolume	O
centers	O
[	O
5,6	O
]	O
.	O

Interstitial	O
lung	O
disease	O
(	O
ILD	O
)	O
,	O
also	O
known	O
as	O
diffuse	O
parenchymal	O
lung	O
disease	O
,	O
comprises	O
a	O
heterogeneous	O
group	O
of	O
diseases	O
characterized	O
by	O
a	O
non	O
-	O
neoplastic	O
,	O
diffuse	O
inflammatory	O
and/or	O
fibrotic	O
pathology	O
affecting	O
the	O
lung	O
parenchyma	O
,	O
usually	O
exhibiting	O
a	O
restrictive	O
defect	O
on	O
pulmonary	O
function	O
testing	O
with	O
reduced	O
gas	O
exchange	O
[	O
7,8	O
]	O
.	O

ILD	O
can	O
be	O
subdivided	O
into	O
fibrotic	O
and	O
non	O
-	O
fibrotic	O
subtypes	O
.	O
Fibrotic	O
subtypes	O
include	O
idiopathic	O
pulmonary	O
fibrosis	O
(	O
IPF	O
)	O
,	O
connective	O
tissue	O
disease	O
-	O
associated	O
ILD	O
(	O
CTD	O
-	O
ILD	O
)	O
,	O
idiopathic	O
non	O
-	O
specific	O
interstitial	O
pneumonia	O
,	O
hypersensitivity	O
pneumonitis	O
,	O
and	O
unclassifiable	O
ILD	O
.	O
Fibrotic	O
ILDs	O
are	O
characterized	O
by	O
reticulation	O
,	O
traction	O
bronchiectasis	O
,	O
and	O
frequently	O
honeycombing	O
on	O
highresolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
.	O
These	O
fibrotic	O
subtypes	O
of	O
ILD	O
are	O
the	O
focus	O
on	O
this	O
research	B-study_type
protocol	I-study_type
.	O

Patients	O
with	O
NSCLC	O
and	O
co	O
-	O
existing	O
fibrotic	O
ILD	O
represent	O
a	O
high	O
-	O
risk	O
group	O
for	O
any	O
type	O
of	O
cancer	O
treatment	O
.	O
Patients	O
with	O
ILD	O
and	O
NSCLC	O
are	O
at	O
risk	O
of	O
both	O
treatment	O
-	O
related	O
toxicities	O
and	O
acute	O
exacerbation	O
of	O
ILD	O
[	O
9	O
]	O
,	O
which	O
can	O
be	O
life	O
-	O
threatening	O
and	O
even	O
fatal	O
.	O
Despite	O
the	O
generally	O
favorable	O
toxicity	O
profile	O
of	O
SABR	O
,	O
emerging	O
data	O
indicate	O
that	O
patients	O
with	O
pre	O
-	O
existing	O
ILD	O
are	O
at	O
particularly	O
high	O
risk	O
of	O
toxicity	O
after	O
SABR	O
.	O
A	O
recent	O
meta	O
-	O
analysis	O
examined	O
outcomes	O
after	O
several	O
different	O
treatments	O
for	O
early	O
-	O
stage	O
lung	O
cancer	O
in	O
patients	O
with	O
ILD	O
[	O
10	O
]	O
.	O
Within	O
the	O
meta	O
-	O
analysis	O
,	O
13	O
published	O
studies	O
(	O
Additional	O
file	O
1	O
)	O
assessed	O
outcomes	O
after	O
SABR	O
.	O
Overall	O
,	O
the	O
use	O
of	O
SABR	O
in	O
patients	O
with	O
earlystage	O
NSCLC	O
and	O
pre	O
-	O
existing	O
ILD	O
was	O
associated	O
with	O
a	O
25	O
%	O
risk	O
of	O
radiation	O
pneumonitis	O
(	O
grade	O
3	O
or	O
higher	O
)	O
and	O
a	O
15	O
%	O
risk	O
of	O
treatment	O
-	O
related	O
death	O
.	O
The	O
risk	O
may	O
be	O
highest	O
in	O
the	O
subset	O
of	O
patients	O
with	O
IPF	O
:	O
SABRrelated	O
mortality	O
was	O
33	O
%	O
in	O
studies	O
limited	O
to	O
IPF	O
patients	O
,	O
and	O
14	O
%	O
in	O
other	O
studies	O
that	O
included	O
only	O
non	O
-	O
IPF	O
fibrotic	O
ILD	O
,	O
or	O
a	O
combination	O
of	O
IPF	O
and	O
non	O
-	O
IPF	O
fibrotic	O
ILD	O
patients	O
(	O
p	O
=	O
0.092	O
)	O
.	O

However	O
,	O
the	O
true	O
rates	O
of	O
toxicity	O
likely	O
differ	O
from	O
the	O
results	O
of	O
this	O
meta	O
-	O
analysis	O
,	O
as	O
nearly	O
all	O
the	O
included	O
studies	O
were	O
retrospective	O
,	O
a	O
wide	O
range	O
of	O
doses	O
were	O
used	O
,	O
and	O
there	O
was	O
substantial	O
variability	O
in	O
outcomes	O
(	O
e.g.	O
,	O
treatment	O
-	O
related	O
death	O
ranged	O
from	O
0	O
to	O
60	O
%	O
across	O
studies	O
)	O
.	O
There	O
is	O
also	O
risk	O
of	O
publication	O
bias	O
favoring	O
the	O
publication	O
studies	O
that	O
show	O
remarkable	O
results	O
(	O
i.e.	O
high	O
rates	O
of	O
toxicity	O
)	O
.	O
Compounding	O
these	O
limitations	O
,	O
attribution	O
of	O
toxicity	O
to	O
radiation	O
is	O
difficult	O
,	O
since	O
ILD	O
exacerbations	O
and	O
radiation	O
pneumonitis	O
may	O
result	O
in	O
similar	O
clinical	O
presentations	O
.	O

Therefore	O
,	O
the	O
true	O
rates	O
of	O
toxicity	O
of	O
SABR	O
in	O
fibrotic	O
ILD	O
patients	O
are	O
likely	O
higher	O
than	O
in	O
the	O
general	O
population	O
,	O
but	O
the	O
precise	O
extent	O
of	O
toxicity	O
remains	O
unknown	O
.	O

Even	O
in	O
the	O
absence	O
of	O
lung	O
cancer	O
,	O
the	O
natural	O
history	O
of	O
ILD	O
is	O
variable	O
.	O
Some	O
patients	O
survive	O
many	O
years	O
with	O
only	O
a	O
modest	O
decline	O
in	O
lung	O
function	O
,	O
whereas	O
other	O
patients	O
experience	O
rapid	O
respiratory	O
decline	O
and	O
death	O
within	O
a	O
few	O
short	O
months	O
.	O

The	O
ILD	O
-	O
GAP	O
(	O
Gender	O
-	O
Age	O
-	O
Physiology	O
)	O
system	O
(	O
Table	O
1	O
)	O
is	O
a	O
prognostic	O
model	O
that	O
takes	O
into	O
account	O
disease	O
type	O
and	O
severity	O
,	O
age	O
,	O
and	O
gender	O
,	O
to	O
predict	O
survival	O
in	O
patients	O
with	O
the	O
major	O
subtypes	O
of	O
chronic	O
ILD	O
,	O
including	O
IPF	O
[	O
11	O
]	O
.	O
The	O
ILD	O
-	O
GAP	O
index	O
assigns	O
an	O
overall	O
score	O
between	O
0	O
and	O
8	O
,	O
with	O
the	O
majority	O
of	O
points	O
assigned	O
based	O
on	O
current	O
pulmonary	O
function	O
.	O
3-year	O
mortality	O
ranges	O
from	O
10	O
%	O
in	O
patients	O
with	O
an	O
index	O
of	O
0	O
-	O
1	O
to	O
75	O
%	O
in	O
patients	O
with	O
an	O
index	O
>	O
5	O
.	O
Notably	O
,	O
all	O
patients	O
with	O
IPF	O
or	O
unclassifiable	O
ILD	O
have	O
a	O
minimum	O
index	O
of	O
2	O
in	O
the	O
ILD	O
-	O
GAP	O
model	O
,	O
reflecting	O
their	O
inferior	O
prognosis	O
.	O
We	O
hypothesize	O
that	O
ILD	O
subtype	O
and	O
severity	O
of	O
pulmonary	O
impairment	O
both	O
influence	O
the	O
risk	O
of	O
radiation	O
toxicity	O
.	O

For	O
patients	O
with	O
ILD	O
and	O
concurrent	O
early	O
-	O
stage	O
lung	O
cancer	O
who	O
are	O
not	O
candidates	O
for	O
surgery	O
,	O
these	O
data	O
showing	O
high	O
rates	O
of	O
toxicity	O
have	O
led	O
to	O
a	O
difficult	O
clinical	O
dilemma	O
,	O
since	O
there	O
are	O
few	O
alternate	O
treatment	O
options	O
.	O
The	O
option	O
of	O
delivering	O
no	O
treatment	O
whatsoever	O
,	O
which	O
avoids	O
any	O
risk	O
of	O
treatment	O
-	O
related	O
toxicity	O
,	O
is	O
associated	O
with	O
a	O
high	O
risk	O
of	O
death	O
due	O
to	O
the	O
lung	O
cancer	O
itself	O
.	O
The	O
median	O
survival	O
for	O
untreated	O
stage	O
I	O
NSCLC	O
is	O
only	O
6	O
-	O
8	O
months	O
,	O
with	O
1-year	O
mortality	O
of	O
60	O
-	O
70	O
%	O
[	O
12	O
]	O
,	O
much	O
higher	O
than	O
the	O
risks	O
associated	O
with	O
SABR	O
treatment	O
.	O
For	O
example	O
,	O
in	O
one	O
study	O
of	O
untreated	O
patients	O
with	O
NSCLC	O
in	O
the	O
U.S.	O
National	O
Cancer	O
Database	O
,	O
the	O
median	O
survival	O
for	O
patients	O
with	O
stage	O
I	O
NSCLC	O
who	O
were	O
unfit	O
for	O
an	O
operation	O
was	O
7.6	O
months	O
[	O
13	O
]	O
.	O
This	O
suggests	O
that	O
even	O
in	O
patients	O
with	O
an	O
ILD	O
-	O
GAP	O
score	O
>	O
5	O
,	O
the	O
risk	O
of	O
death	O
due	O
to	O
lung	O
cancer	O
within	O
1	O
year	O
exceeds	O
the	O
risk	O
of	O
death	O
due	O
to	O
ILD	O
or	O
complications	O
of	O
SABR	O
.	O

As	O
a	O
result	O
,	O
patients	O
with	O
ILD	O
and	O
early	O
-	O
stage	O
NSCLC	O
are	O
often	O
advised	O
,	O
after	O
discussion	O
of	O
their	O
case	O
at	O
a	O
multidisciplinary	O
conference	O
,	O
that	O
treatment	O
with	O
SABR	O
provides	O
the	O
best	O
chance	O
of	O
local	O
control	O
and	O
cure	O
,	O
but	O
that	O
SABR	O
is	O
associated	O
with	O
an	O
appreciable	O
risk	O
of	O
treatment	O
-	O
related	O
toxicity	O
.	O
For	O
patients	O
undergoing	O
SABR	O
under	O
this	O
scenario	O
,	O
the	O
optimal	O
dose	O
and	O
fractionation	O
is	O
unknown	O
.	O

It	O
is	O
possible	O
that	O
currently	O
-	O
used	O
doses	O
and	O
fractionations	O
of	O
SABR	O
,	O
when	O
given	O
with	O
strict	O
planning	O
criteria	O
to	O
minimize	O
the	O
risk	O
of	O
lung	O
toxicity	O
,	O
have	O
only	O
a	O
modest	O
risk	O
of	O
treatment	O
-	O
related	O
toxicity	O
and	O
represent	O
the	O
best	O
possible	O
approach	O
.	O

Alternatively	O
,	O
it	O
may	O
be	O
necessary	O
to	O
reduce	O
the	O
dose	O
of	O
SABR	O
,	O
at	O
the	O
risk	O
of	O
compromising	O
tumor	O
control	O
.	O
Adjustments	O
to	O
the	O
SABR	O
fractionation	O
schedule	O
may	O
reduce	O
the	O
risk	O
of	O
toxicity	O
,	O
while	O
still	O
maintaining	O
some	O
benefit	O
.	O
Radiation	O
dose	O
is	O
expressed	O
in	O
Gray	O
(	O
Gy	O
)	O
,	O
with	O
most	O
SABR	O
treatments	O
delivering	O
approximately	O
a	O
total	O
dose	O
50	O
-	O
60	O
Gy	O
.	O
This	O
total	O
dose	O
is	O
divided	O
up	O
into	O
smaller	O
individual	O
fractions	O
of	O
radiation	O
.	O
Conventional	O
radiotherapy	O
employs	O
fraction	O
sizes	O
of	O
approximately	O
2	O
Gy	O
per	O
day	O
,	O
5	O
days	O
per	O
week	O
,	O
and	O
would	O
require	O
30	O
fractions	O
to	O
deliver	O
60	O
Gy	O
.	O
This	O
prolonged	O
treatment	O
time	O
(	O
i.e.	O
6	O
weeks	O
of	O
treatment	O
)	O
may	O
allow	O
for	O
tumor	O
repopulation	O
,	O
compromising	O
treatment	O
outcomes	O
.	O
With	O
SABR	O
,	O
common	O
fractionations	O
include	O
54	O
Gy	O
in	O
3	O
fractions	O
(	O
i.e.	O
18	O
Gy	O
per	O
fraction	O
)	O
,	O
48	O
Gy	O
in	O
4	O
fractions	O
(	O
i.e.	O
12	O
Gy	O
per	O
fraction	O
)	O
and	O
60	O
Gy	O
in	O
8	O
fractions	O
(	O
i.e.	O
7.5	O
Gy	O
per	O
day	O
)	O
.	O
SABR	O
fractions	O
are	O
often	O
given	O
every	O
second	O
day	O
(	O
or	O
even	O
more	O
widely	O
spaced	O
)	O
to	O
maximize	O
the	O
time	O
for	O
normal	O
tissue	O
repair	O
between	O
fractions	O
.	O

To	O
compare	O
the	O
potency	O
of	O
these	O
different	O
radiation	O
dose	O
fractionations	O
,	O
a	O
formula	O
called	O
the	O
biologically	O
effective	O
dose	O
(	O
BED	O
)	O
is	O
used	O
.	O
BED	O
takes	O
into	O
account	O
the	O
total	O
number	O
of	O
fractions	O
,	O
the	O
dose	O
per	O
fraction	O
,	O
and	O
the	O
intrinsic	O
radiation	O
response	O
curve	O
of	O
the	O
individual	O
tissues	O
treated	O
.	O
BED	O
is	O
calculated	O
according	O
to	O
the	O
formula	O

α	O
=	O
β	O
Þ	O
,	O
where	O
α	O
/	O
β	O
is	O
the	O
alpha	O
/	O
beta	O
ratio	O
of	O
the	O
tissue	O
(	O
assumed	O
to	O
be	O
10	O
Gy	O
for	O
NSCLC	O
and	O
3	O
Gy	O
for	O
normal	O
lung	O
tissue	O
)	O
,	O
n	O
is	O
the	O
total	O
number	O
of	O
fractions	O
of	O
radiation	O
therapy	O
and	O
d	O
is	O
the	O
dose	O
per	O
fraction	O
.	O
Table	O
1	O
The	O
ILD	O
-	O
GAP	O
model	O
,	O
reproduced	O
from	O
Ryerson	O
et	O
al	O
.	O
[	O
11	O
]	O
Predictor	O
Points	O

The	O
BED	O
10	O
is	O
used	O
to	O
predict	O
the	O
response	O
of	O
tumor	O
,	O
and	O
also	O
of	O
acutely	O
-	O
responding	O
normal	O
tissues	O
(	O
e.g.	O
skin	O
and	O
mucosa	O
)	O
.	O
A	O
higher	O
BED	O
10	O
is	O
associated	O
with	O
a	O
higher	O
chance	O
of	O
local	O
control	O
,	O
and	O
a	O
value	O
of	O
BED	O
10	O
≥	O
100	O
is	O
considered	O
a	O
minimum	O
threshold	O
for	O
SABR	O
[	O
14	O
]	O
.	O
The	O
BED	O
3	O
is	O
used	O
to	O
predict	O
the	O
response	O
of	O
normal	O
lung	O
parenchyma	O
(	O
i.e.	O
the	O
risk	O
of	O
radiation	O
pneumonitis	O
)	O
.	O
A	O
lower	O
BED	O
3	O
is	O
expected	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
pneumonitis	O
.	O
However	O
,	O
efforts	O
to	O
reduce	O
the	O
BED	O
3	O
will	O
also	O
lead	O
to	O
reductions	O
in	O
BED	O
10	O
,	O
compromising	O
the	O
effectiveness	O
of	O
SABR	O
.	O
(	O
For	O
specific	O
BED	O
10	O
and	O
BED	O
3	O
values	O
used	O
in	O
the	O
studies	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
,	O
see	O
Additional	O
file	O
1	O
)	O
.	O

During	O
the	O
design	O
of	O
this	O
trial	B-study_type
in	O
2016	O
-	O
17	O
,	O
several	O
options	O
were	O
considered	O
and	O
ultimately	O
discussed	O
at	O
a	O
meeting	O
of	O
the	O
Canadian	O
Pulmonary	O
Radiotherapy	O
Investigators	O
'	O
(	O
CAPRI	O
)	O
Group	O
at	O
the	O
September	O
2017	O
Canadian	O
Association	O
of	O
Radiation	O
Oncology	O
Annual	O
Meeting	O
.	O
Two	O
main	O
alternative	O
approaches	O
were	O
considered	O
:	O

Option	O
1	O
:	O
Conduct	O
a	O
phase	O
II	O
trial	O
using	O
a	O
standard	O
dose	O
of	O
SABR	O
that	O
has	O
a	O
high	O
chance	O
of	O
local	O
control	O
;	O
specifically	O
,	O
50	O
Gy	O
in	O
5	O
fractions	O
(	O
BED	O
10	O
=	O
100	O
)	O
,	O
with	O
careful	O
attention	O
to	O
minimization	O
of	O
lung	O
dose	O
,	O
and	O
built	O
-	O
in	O
dose	O
de	O
-	O
escalation	O
if	O
toxicity	O
is	O
excessive	O
.	O
Option	O
2	O
.	O
Conduct	O
a	O
phase	O
I	O
trial	O
starting	O
with	O
a	O
less	O
-	O
potent	O
dose	O
of	O
radiation	O
to	O
potentially	O
minimize	O
toxicity	O
,	O
and	O
then	O
escalate	O
the	O
dose	O
thereafter	O
.	O
This	O
would	O
be	O
expected	O
to	O
result	O
in	O
lower	O
local	O
control	O
.	O

The	O
CAPRI	O
concluded	O
that	O
option	O
2	O
was	O
unfavorable	O
for	O
3	O
reasons	O
:	O
it	O
would	O
subject	O
patients	O
to	O
a	O
higher	O
risk	O
of	O
local	O
recurrence	O
,	O
which	O
itself	O
could	O
be	O
expected	O
to	O
be	O
fatal	O
;	O
it	O
is	O
unclear	O
that	O
reducing	O
to	O
the	O
lower	O
dose	O
levels	O
would	O
impact	O
toxicity	O
substantially	O
;	O
and	O
many	O
attendees	O
stated	O
that	O
a	O
common	O
current	O
approach	O
outside	O
of	O
a	O
trial	O
is	O
to	O
offer	O
full	O
-	O
dose	O
radiotherapy	O
after	O
a	O
careful	O
discussion	O
with	O
patients	O
.	O

There	O
is	O
precedent	O
for	O
this	O
approach	O
,	O
as	O
two	O
other	O
phase	O
I	O
trials	O
of	O
SABR	O
have	O
started	O
at	O
therapeutic	O
doses	O
:	O
RTOG	O
0813	O
for	O
central	O
tumors	O
(	O
started	O
at	O
50	O
Gy	O
in	O
5	O
fractions	O
before	O
escalating	O
to	O
60	O
Gy	O
in	O
5	O
fractions	O
)	O
and	O
SUNSET	O
for	O
ultra	O
-	O
central	O
tumors	O
(	O
starting	O
at	O
60	O
Gy	O
in	O
8	O
fractions	O
,	O
currently	O
underway	O
)	O
[	O
15	O
]	O
.	O

Pulmonary	O
toxicity	O
was	O
not	O
chosen	O
as	O
a	O
primary	O
endpoint	O
because	O
it	O
is	O
very	O
difficult	O
to	O
distinguish	O
between	O
radiation	O
pneumonitis	O
and	O
ILD	O
exacerbations	O
.	O
The	O
patients	O
included	O
herein	O
are	O
expected	O
to	O
develop	O
ILD	O
exacerbations	O
as	O
part	O
of	O
the	O
natural	O
history	O
of	O
their	O
ILD	O
,	O
and	O
they	O
are	O
at	O
risk	O
of	O
ILDrelated	O
death	O
,	O
which	O
is	O
difficult	O
to	O
distinguish	O
from	O
pneumonitis	O
-	O
related	O
death	O
.	O
Erroneous	O
attribution	O
of	O
ILD	O
exacerbations	O
to	O
radiation	O
could	O
lead	O
to	O
the	O
incorrect	O
conclusion	O
that	O
the	O
radiation	O
dose	O
should	O
be	O
lowered	O
.	O
In	O
essence	O
,	O
the	O
subjectivity	O
of	O
assigning	O
the	O
cause	O
of	O
toxicity	O
should	O
not	O
be	O
part	O
of	O
the	O
primary	O
outcome	O
due	O
to	O
the	O
risk	O
of	O
misattribution	O
.	O
However	O
,	O
pulmonary	O
toxicity	O
outcomes	O
will	O
be	O
closely	O
monitored	O
in	O
this	O
trial	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
was	O
chosen	O
as	O
the	O
primary	O
outcome	O
as	O
it	O
objectively	O
reflects	O
the	O
potential	O
benefits	O
of	O
treatment	O
(	O
i.e.	O
extended	O
survival	O
)	O
,	O
the	O
harms	O
of	O
treatment	O
(	O
grade	O
5	O
toxicity	O
)	O
,	O
and	O
the	O
natural	O
history	O
of	O
the	O
ILD	O
disease	O
process	O
itself	O
.	O
Since	O
the	O
median	O
survival	O
of	O
untreated	O
Stage	O
I	O
NSCLC	O
in	O
inoperable	O
patients	O
is	O
consistently	O
reported	O
as	O
<	O
1	O
year	O
(	O
as	O
noted	O
above	O
)	O
,	O
we	O
hypothesize	O
that	O
the	O
use	O
of	O
SABR	O
can	O
achieve	O
a	O
median	O
OS	O
of	O
>	O
1	O
year	O
in	O
patients	O
with	O
ILD	O
.	O
Though	O
pulmonary	O
toxicity	O
is	O
not	O
to	O
be	O
the	O
primary	O
outcome	O
in	O
this	O
trial	O
,	O
it	O
will	O
nevertheless	O
be	O
closely	O
monitored	O
to	O
determine	O
whether	O
subsequently	O
-	O
enrolled	O
patients	O
will	O
receive	O
a	O
deescalated	O
radiation	O
regimen	O
.	O

SABR	O
will	O
be	O
considered	O
worthwhile	O
if	O
median	O
OS	O
is	O
>	O
1	O
year	O
with	O
an	O
acceptable	O
risk	O
of	O
toxicity	O
,	O
defined	O
as	O
a	O
grade	O
3	O
or	O
4	O
pulmonary	O
toxicity	O
rate	O
of	O
less	O
than	O
35	O
%	O
and	O
a	O
risk	O
of	O
treatment	O
-	O
related	O
death	O
of	O
less	O
than	O
15	O
%	O
.	O

This	O
is	O
a	O
prospective	B-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
of	O
SABR	O
in	O
patients	O
with	O
co	O
-	O
existent	O
interstitial	O
lung	O
disease	O
,	O
to	O
determine	O
oncologic	O
and	O
toxicity	O
outcomes	O
.	O
Patients	O
will	O
be	O
divided	O
into	O
3	O
separate	O
cohorts	O
based	O
on	O
the	O
ILD	O
-	O
GAP	O
index	O
(	O
Table	O
1	O
)	O
.	O

The	O
Study	O
Schema	O
can	O
be	O
found	O
in	O
Fig	O
.	O
1	O
.	O
The	O
required	O
sample	O
size	O
is	O
39	O
.	O
Patients	O
who	O
meet	O
eligibility	O
criteria	O
but	O
decline	O
to	O
pursue	O
radiation	O
and	O
patients	O
for	O
whom	O
SABR	O
can	O
not	O
be	O
delivered	O
at	O
the	O
recommended	O
doses	O
due	O
to	O
inacceptable	O
doses	O
to	O
normal	O
tissues	O
at	O
risk	O
will	O
be	O
asked	O
to	O
consent	O
to	O
limited	O
ongoing	O
follow	O
-	O
up	O
only	O
.	O

Overall	O
survival	O
:	O
defined	O
as	O
time	O
from	O
enrollment	O
to	O
death	O
from	O
any	O
cause	O
Changes	O
in	O
pulmonary	O
function	O
tests	O
,	O
including	O
diffusing	O
capacity	O
of	O
the	O
lungs	O
for	O
carbon	O
monoxide	O
(	O
DLCO	O
)	O
,	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV	O
1	O
)	O
,	O
and	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
.	O
Exploratory	O
quantitative	O
analysis	O
of	O
HRCT	O
features	O
(	O
i.e.	O
radiomics	O
)	O
Analysis	O
of	O
outcomes	O
for	O
patients	O
who	O
otherwise	O
meet	O
the	O
study	O
enrollment	O
criteria	O
but	O
decline	O
radiotherapy	O
.	O

Stage	O
T1	O
-	O
2	O
,	O
N0	O
,	O
M0	O
(	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
)	O
Staging	O
,	O
8th	O
Editioni.e	O
.	O
tumor	O
size	O
≤5	O
cm	O
)	O
prior	O
to	O
registration	O
.	O
Not	O
a	O
candidate	O
for	O
surgical	O
resection	O
,	O
determined	O
by	O
any	O
of	O
the	O
following	O
:	O

Consultation	O
with	O
a	O
thoracic	O
surgeon	O
Discussion	O
at	O
multidisciplinary	O
tumour	O
conference	O
with	O
a	O
surgeon	O
present	O
Patient	O
refusal	O
of	O
surgery	O
Pathologically	O
(	O
histologically	O
or	O
cytologically	O
)	O
proven	O
diagnosis	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
is	O
not	O
required	O
,	O
but	O
strongly	O
recommended	O
.	O

If	O
the	O
risk	O
of	O
biopsy	O
is	O
unacceptable	O
,	O
pathologic	O
confirmation	O
is	O
not	O
required	O
providing	O
there	O
is	O
growth	O
over	O
time	O
on	O
CT	O
imaging	O
and/or	O
fluorodeoxyglucose	O
(	O
FDG	O
)	O
avidity	O
that	O
is	O
strongly	O
suggestive	O
of	O
a	O
primary	O
NSCLC	O
.	O

History	O
/	O
physical	O
examination	O
within	O
4	O
weeks	O
prior	O
to	O
registration	O
,	O
including	O
documentation	O
of	O
current	O
medications	O
and	O
home	O
oxygen	O
use	O
.	O
HRCT	O
scan	O
of	O
the	O
thorax	O
(	O
with	O
contrast	O
unless	O
medically	O
contraindicated	O
)	O
within	O
12	O
weeks	O
of	O
registration	O
.	O
Slice	O
thickness	O
must	O
be	O
1.5	O
mm	O
or	O
less	O
with	O
continuous	O
(	O
i.e.	O
non	O
-	O
gapped	O
)	O
images	O
.	O
Each	O
centre	O
must	O
communicate	O
with	O
their	O
radiologists	O
to	O
ensure	O
that	O
CT	O
scans	O
are	O
done	O
using	O
protocols	O
adequate	O
for	O
ILD	O
.	O
The	O
primary	O
tumor	O
dimensions	O
will	O
be	O
measured	O
on	O
CT	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
scan	O
of	O
the	O
entire	O
body	O
within	O
8	O
weeks	O
of	O
registration	O
,	O
using	O
FDG	O
.	O
Pre	O
-	O
bronchodilator	O
spirometry	O
,	O
lung	O
volumes	O
and	O
diffusion	O
capacity	O
within	O
8	O
weeks	O
prior	O
to	O
treatment	O
.	O
Assessment	O
by	O
a	O
respirologist	O
/	O
pulmonologist	O
within	O
4	O
weeks	O
of	O
enrollment	O
,	O
for	O
the	O
following	O
purposes	O
:	O
To	O
optimize	O
pulmonary	O
function	O
and	O
treatment	O
of	O
ILD	O
,	O
if	O
possible	O
.	O

To	O
document	O
subtype	O
of	O
ILD	O
,	O
and	O
whether	O
possible	O
,	O
probable	O
or	O
definite	O
IPF	O
exists	O
.	O
To	O
document	O
key	O
clinical	O
features	O
related	O
to	O
ILD	O
(	O
per	O
a	O
questionnaire	O
)	O
,	O
required	O
for	O
central	O
review	O
.	O
Mediastinal	O
lymph	O
node	O
sampling	O
by	O
any	O
technique	O
is	O
allowed	O
but	O
not	O
required	O
.	O
Hilar	O
or	O
mediastinal	O
lymph	O
nodes	O
≤1	O
cm	O
in	O
short	O
-	O
axis	O
diameter	O
with	O
no	O
pathological	O
PET	O
uptake	O
will	O
be	O
considered	O
N0	O
.	O
Patients	O
with	O
hilar	O
or	O
mediastinal	O
lymph	O
nodes	O
>	O
1	O
cm	O
in	O
short	O
-	O
axis	O
diameter	O
on	O
CT	O
or	O
lymph	O
nodes	O
with	O
abnormal	O
PET	O
uptake	O
may	O
still	O
be	O
eligible	O
if	O
biopsies	O
of	O
suspicious	O
lymph	O
nodes	O
are	O
negative	O
for	O
malignancy	O
.	O
Assessment	O
for	O
brain	O
metastases	O
is	O
not	O
mandated	O
unless	O
suspicious	O
symptoms	O
are	O
present	O
,	O
in	O
which	O
case	O
a	O
contrast	O
-	O
enhanced	O
magnetic	O
-	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
the	O
brain	O
is	O
required	O
.	O
If	O
MRI	O
is	O
contra	O
-	O
indicated	O
due	O
to	O
claustrophobia	O
or	O
metal	O
implants	O
(	O
or	O
other	O
reason	O
)	O
,	O
then	O
CT	O
is	O
allowed	O
.	O

A	O
central	O
review	O
of	O
the	O
standardized	O
clinical	O
data	O
,	O
HRCT	O
,	O
and	O
any	O
previous	O
lung	O
biopsies	O
(	O
if	O
available	O
)	O
will	O
be	O
done	O
to	O
confirm	O
subtype	O
of	O
ILD	O
.	O
The	O
central	O
review	O
team	O
will	O
include	O
a	O
pathologist	O
,	O
respirologist	O
,	O
and	O
radiologist	O
.	O

Clinical	O
/	O
Laboratory	O
Data	O
:	O
Including	O
clinical	O
history	O
,	O
symptoms	O
with	O
date	O
of	O
onset	O
,	O
smoking	O
history	O
(	O
including	O
pack	O
years	O
and	O
quit	O
date	O
)	O
,	O
exposures	O
,	O
CTD	O
features	O
,	O
serology	O
(	O
normal	O
and	O
abnormal	O
)	O
,	O
pulmonary	O
function	O
tests	O
,	O
and	O
the	O
subtype	O
of	O
ILD	O
as	O
determined	O
by	O
the	O
treating	O
respirologist	O
.	O
Pathology	O
:	O
slides	O
(	O
to	O
be	O
returned	O
)	O
and	O
pathology	O
reports	O
Radiology	O
:	O
Digital	O
Imaging	O
and	O
Communications	O
in	O
Medicine	O
(	O
DICOM	O
)	O
images	O
of	O
thoracic	O
CT	O
scans	O
(	O
through	O
Quantitative	O
Imaging	O
for	O
Personalized	O
Cancer	O
Medicine	O
(	O
QIPCM	O
)	O
)	O
and	O
radiology	O
reports	O

Patients	O
will	O
be	O
assigned	O
to	O
a	O
category	O
of	O
fibrotic	O
ILD	O
(	O
i.e.	O
IPF	O
,	O
idiopathic	O
non	O
-	O
specific	O
interstitial	O
pneumonia	O
,	O
CTD	O
-	O
ILD	O
,	O
hypersensitivity	O
pneumonitis	O
,	O
Unclassifiable	O
ILD	O
/	O
other	O
)	O
and	O
an	O
ILD	O
-	O
GAP	O
score	O
will	O
be	O
assigned	O
.	O

During	O
radiation	O
,	O
patients	O
are	O
allowed	O
to	O
receive	O
antifibrotic	O
agents	O
(	O
e.g.	O
nintedanib	O
)	O
or	O
steroids	O
,	O
if	O
those	O
are	O
part	O
of	O
their	O
current	O
ILD	O
treatment	O
regimen	O
.	O
Other	O
immunosuppressive	O
drugs	O
such	O
as	O
mycophenolate	O
,	O
azathioprine	O
,	O
cyclophosphamide	O
,	O
and	O
rituximab	O
must	O
be	O
stopped	O
for	O
2	O
weeks	O
prior	O
and	O
2	O
weeks	O
after	O
treatment	O
.	O

The	O
total	O
dose	O
will	O
be	O
50	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
5	I-arm_dosage
fractions	I-arm_dosage
,	I-arm_dosage
given	I-arm_dosage
every	I-arm_dosage
second	I-arm_dosage
day	I-arm_dosage
.	O
In	O
the	O
event	O
that	O
the	O
dose	O
is	O
de	O
-	O
escalated	O
to	O
50	O
Gy	O
in	O
10	O
fractions	O
or	O
45	O
Gy	O
in	O
15	O
fractions	O
,	O
then	O
the	O
same	O
prescribing	O
principles	O
apply	O
(	O
i.e.	O
using	O
a	O
SABR	O
-	O
like	O
technique	O
)	O
but	O
these	O
latter	O
two	O
fractionations	O
are	O
given	O
daily	O
.	O

A	O
stable	O
and	O
consistent	O
immobilization	O
technique	O
is	O
advised	O
for	O
all	O
patients	O
and	O
all	O
fractions	O
to	O
maximize	O
interfraction	O
reproducibility	O
.	O
Patients	O
should	O
be	O
comfortably	O
immobilized	O
during	O
treatment	O
to	O
minimize	O
unnecessary	O
motion	O
due	O
to	O
discomfort	O
and	O
maximize	O
intra	O
-	O
fraction	O
reproducibility	O
.	O
Different	O
immobilization	O
systems	O
may	O
be	O
utilized	O
including	O
a	O
thermoplastic	O
shell	O
,	O
alpha	O
-	O
cradle	O
,	O
Vac	O
-	O
Lok	O
bag	O
or	O
none	O
,	O
per	O
institutional	O
standard	O
.	O
The	O
immobilization	O
setup	O
should	O
be	O
identical	O
to	O
that	O
used	O
at	O
simulation	O
time	O
.	O

Patients	O
will	O
undergo	O
planning	O
CT	O
simulation	O
with	O
a	O
4dimensional	O
(	O
4D)-CT	O
,	O
unless	O
being	O
treated	O
with	O
a	O
system	O
that	O
accounts	O
for	O
motion	O
without	O
4D	O
-	O
CT	O
(	O
e.g.	O
Cyber	O
-	O
Knife	O
)	O
.	O
The	O
use	O
of	O
IV	O
contrast	O
is	O
not	O
required	O
.	O
Axial	O
CT	O
images	O
will	O
be	O
obtained	O
throughout	O
the	O
region	O
of	O
interest	O
.	O
At	O
each	O
center	O
,	O
the	O
local	O
physicist	O
or	O
CT	O
-	O
simulation	O
therapists	O
will	O
review	O
the	O
4D	O
-	O
CT	O
images	O
and	O
will	O
perform	O
the	O
following	O
quality	O
assurance	O
procedures	O
:	O
ensuring	O
all	O
end	O
inspiration	O
(	O
0	O
%	O
)	O
tags	O
exist	O
and	O
are	O
in	O
the	O
right	O
place	O
;	O
ensuring	O
that	O
the	O
quality	O
of	O
the	O
4D	O
-	O
CT	O
images	O
are	O
acceptable	O
(	O
determined	O
by	O
Physics	O
or	O
CTsimulation	O
therapists	O
if	O
standard	O
at	O
that	O
institution	O
)	O
;	O
and	O
that	O
motion	O
measurements	O
in	O
all	O
3	O
directions	O
are	O
performed	O
.	O

Motion	O
assessment	O
is	O
mandatory	O
.	O
The	O
specific	O
target	O
motion	O
of	O
each	O
patient	O
must	O
be	O
quantified	O
to	O
determine	O
if	O
additional	O
motion	O
management	O
strategies	O
are	O
required	O
.	O
If	O
the	O
tumor	O
excursion	O
is	O
≤1	O
cm	O
,	O
the	O
internal	O
target	O
volume	O
(	O
ITV	O
)	O
approach	O
is	O
sufficient	O
for	O
treatment	O
planning	O
and	O
dose	O
-	O
volume	O
histogram	O
(	O
DVH	O
)	O
analysis	O
,	O
although	O
standard	O
institutional	O
motion	O
management	O
strategies	O
may	O
be	O
used	O
as	O
well	O
.	O
The	O
design	O
of	O
the	O
target	O
volume	O
should	O
cover	O
the	O
primary	O
lung	O
cancer	O
during	O
breathing	O
.	O
If	O
the	O
tumor	O
excursion	O
is	O
>	O
1	O
cm	O
,	O
acceptable	O
motion	O
management	O
techniques	O
for	O
reducing	O
target	O
motion	O
≤1	O
cm	O
include	O
abdominal	O
compression	O
,	O
active	O
breathing	O
control	O
,	O
active	O
breath	O
hold	O
,	O
free	O
-	O
breathing	O
gating	O
,	O
gated	O
breath	O
hold	O
or	O
robotic	O
tumor	O
tracking	O
(	O
direct	O
soft	O
tissue	O
or	O
fiducial	O
tracking	O
)	O
.	O

The	O
target	O
lesion	O
will	O
be	O
outlined	O
by	O
an	O
appropriately	O
trained	O
physician	O
and	O
designated	O
the	O
gross	O
tumor	O
volume	O
(	O
GTV	O
)	O
on	O
both	O
the	O
inspiratory	O
and	O
expiratory	O
CT	O
images	O
.	O
The	O
target	O
will	O
generally	O
be	O
drawn	O
using	O
CT	O
pulmonary	O
windows	O
;	O
however	O
,	O
soft	O
tissue	O
windows	O
should	O
be	O
used	O
to	O
avoid	O
inclusion	O
of	O
adjacent	O
vessels	O
,	O
atelectasis	O
,	O
mediastinal	O
or	O
chest	O
wall	O
structures	O
within	O
the	O
GTV	O
.	O
This	O
target	O
will	O
not	O
be	O
enlarged	O
whatsoever	O
(	O
i.e.	O
no	O
"	O
margin	O
"	O
for	O
presumed	O
microscopic	O
extension	O
)	O
;	O
rather	O
,	O
it	O
will	O
only	O
include	O
areas	O
consistent	O
with	O
gross	O
tumor	O
(	O
i.e.	O
,	O
the	O
GTV	O
and	O
the	O
Clinical	O
Target	O
Volume	O
,	O
CTV	O
,	O
are	O
identical	O
)	O
.	O
PET	O
images	O
may	O
be	O
used	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
oncologist	O
,	O
but	O
consistent	O
with	O
International	O
Atomic	O
Energy	O
Agency	O
(	O
IAEA	O
)	O
guidelines	O
,	O
CT	O
should	O
be	O
used	O
to	O
determine	O
the	O
boundary	O
between	O
tumor	O
and	O
normal	O
tissue	O
,	O
as	O
PET	O
images	O
are	O
subject	O
to	O
thresholding	O
effects	O
.	O

An	O
ITV	O
is	O
generated	O
from	O
the	O
outlined	O
GTV	O
on	O
the	O
inspiratory	O
and	O
expiratory	O
CT	O
datasets	O
.	O
An	O
additional	O
0.5	O
cm	O
will	O
be	O
added	O
in	O
all	O
planes	O
to	O
constitute	O
the	O
planning	O
treatment	O
volume	O
(	O
PTV	O
)	O
.	O
Depending	O
on	O
institutional	O
practice	O
,	O
the	O
Exhale	O
phase	O
may	O
be	O
used	O
as	O
a	O
primary	O
dataset	O
for	O
treatment	O
planning	O
with	O
fusion	O
of	O
the	O
inhale	O
,	O
maximum	O
intensity	O
projection	O
(	O
MIP	O
)	O
and	O
average	O
.	O
Alternatively	O
,	O
the	O
Average	O
phase	O
may	O
also	O
be	O
used	O
as	O
the	O
primary	O
dataset	O
.	O
The	O
GTVs	O
contoured	O
on	O
these	O
datasets	O
will	O
define	O
the	O
internal	O
GTV	O
(	O
IGTV	O
)	O
.	O
This	O
contour	O
may	O
be	O
used	O
to	O
define	O
the	O
PTV	O
using	O
standard	O
margins	O
or	O
for	O
image	O
registration	O
with	O
cone	O
beam	O
CT	O
(	O
CBCT	O
)	O
.	O

For	O
respiratory	O
gating	O
treatment	O
,	O
if	O
used	O
,	O
planning	O
will	O
be	O
performed	O
on	O
a	O
subset	O
average	O
CT	O
dataset	O
(	O
usually	O
labeled	O
either	O
30	O
-	O
60	O
%	O
Avg	O
CT	O
or	O
40	O
-	O
70	O
%	O
Avg	O
CT	O
)	O
generated	O
by	O
Physics	O
.	O
This	O
is	O
an	O
average	O
CT	O
over	O
the	O
intended	O
gated	O
interval	O
.	O
Therefore	O
,	O
the	O
GTV	O
that	O
is	O
delineated	O
on	O
this	O
scan	O
will	O
incorporate	O
residual	O
motion	O
in	O
the	O
intended	O
gated	O
interval	O
.	O
The	O
0	O
%	O
phase	O
will	O
also	O
be	O
fused	O
to	O
this	O
dataset	O
.	O
The	O
PTV	O
for	O
planning	O
will	O
include	O
the	O
GTV	O
delineated	O
on	O
the	O
subset	O
average	O
CT	O
and	O
setup	O
uncertainty	O
.	O
The	O
GTV_0	O
%	O
should	O
also	O
be	O
delineated	O
and	O
combined	O
with	O
the	O
GTV	O
delineated	O
on	O
the	O
subset	O
average	O
CT	O
to	O
define	O
an	O
additional	O
volume	O
labeled	O
IGTV	O
_	O
CBCT	O
.	O
This	O
contour	O
may	O
be	O
used	O
for	O
image	O
guidance	O
with	O
CBCT	O
only	O
.	O

Treatment	O
can	O
be	O
delivered	O
using	O
static	O
beams	O
(	O
either	O
3D	O
-	O
conformal	O
radiotherapy	O
or	O
intensity	O
-	O
modulated	O
)	O
or	O
rotational	O
therapy	O
(	O
volumetric	O
modulated	O
arc	O
therapy	O
,	O
or	O
Tomotherapy	O
)	O
.	O
Only	O
photon	O
(	O
X	O
-	O
ray	O
)	O
beams	O
of	O
10	O
MV	O
or	O
less	O
produced	O
by	O
linear	O
accelerators	O
will	O
be	O
used	O
.	O

For	O
purposes	O
of	O
dose	O
planning	O
and	O
calculation	O
of	O
monitor	O
units	O
for	O
actual	O
treatment	O
,	O
this	O
protocol	O
will	O
require	O
tissue	O
density	O
heterogeneity	O
correction	O
.	O
Successful	O
treatment	O
planning	O
will	O
require	O
accomplishment	O
of	O
all	O
of	O
the	O
following	O
criteria	O
:	O

Prescription	O
isodose	O
surface	O
:	O
The	O
prescription	O
isodose	O
surface	O
will	O
conformally	O
cover	O
95	O
%	O
of	O
the	O
target	O
volume	O
(	O
PTV	O
)	O
,	O
such	O
that	O
99	O
%	O
of	O
the	O
PTV	O
will	O
also	O
receive	O
at	O
least	O
90	O
%	O
of	O
the	O
prescription	O
dose	O
.	O
(	O
PTV	O
D95	O
%	O
=	O
100	O
%	O
of	O
prescription	O
dose	O
and	O
D99	O
%	O
=	O
90	O
%	O
of	O
prescription	O
dose	O
)	O
Target	O
dose	O
heterogeneity	O
:	O
The	O
dose	O
at	O
the	O
prescription	O
isodose	O
surface	O
must	O
be	O
between	O
60	O
and	O
90	O
%	O
(	O
inclusive	O
)	O
of	O
the	O
dose	O
at	O
the	O
normalization	O
point	O
of	O
the	O
plan	O
.	O
The	O
prescription	O
isodose	O
surface	O
is	O
typically	O
80	O
%	O
of	O
the	O
dose	O
at	O
the	O
normalization	O
point	O
,	O
though	O
the	O
allowed	O
range	O
enables	O
flexibility	O
to	O
optimize	O
dose	O
to	O
organs	O
at	O
risk	O
(	O
OARs	O
)	O
,	O
especially	O
the	O
lung	O
.	O
High	O
dose	O
spillage	O
(	O
as	O
per	O
the	O
RTOG	O
0813	O
[	O
16	O
]	O
protocol	O
)	O
:	O

Location	O
:	O
Areas	O
with	O
dose	O
>	O
105	O
%	O
of	O
the	O
prescription	O
dose	O
should	O
be	O
located	O
primarily	O
within	O
the	O
PTV	O
itself	O
.	O
The	O
cumulative	O
volume	O
outside	O
the	O
PTV	O
volume	O
with	O
dose	O
>	O
105	O
%	O
of	O
prescription	O
dose	O
should	O
be	O
no	O
more	O
than	O
15	O
%	O
of	O
the	O
PTV	O
volume	O
.	O
Volume	O
:	O
Conformality	O
of	O
PTV	O
coverage	O
will	O
be	O
determined	O
by	O
the	O
R100	O
(	O
the	O
ratio	O
of	O
the	O
volume	O
of	O
the	O
prescription	O
isodose	O
to	O
the	O
volume	O
of	O
the	O
PTV	O
)	O
,	O
R50	O
(	O
The	O
ratio	O
of	O
the	O
volume	O
of	O
50	O
%	O
of	O
the	O
prescription	O
dose	O
isodose	O
to	O
the	O
volume	O
of	O
the	O
PTV	O
)	O
,	O
and	O
D2	O
cm	O
(	O
the	O
maximum	O
total	O
dose	O
over	O
all	O
fractions	O
in	O
Gray	O
(	O
Gy	O
)	O
to	O
any	O
point	O
2	O
cm	O
or	O
greater	O
away	O
from	O
the	O
PTV	O
in	O
any	O
direction	O
)	O
,	O
as	O
per	O
Table	O
3	O
.	O
All	O
critical	O
organ	O
dose	O
-	O
volume	O
constraints	O
in	O
Table	O
2	O
must	O
be	O
respected	O
.	O
Lung	O
dose	O
constraints	O
may	O
not	O
be	O
exceeded	O
for	O
any	O
reason	O
.	O

Dose	O
-	O
volume	O
histograms	O
must	O
be	O
generated	O
for	O
each	O
critical	O
structure	O
so	O
that	O
the	O
dose	O
-	O
volume	O
constraints	O
can	O
be	O
evaluated	O
.	O
Instructions	O
for	O
contouring	O
the	O
critical	O
structures	O
are	O
provided	O
below	O
and	O
reflect	O
common	O
radiotherapy	O
contouring	O
procedures	O
,	O
as	O
per	O
RTOG	O
0813	O
[	O
16	O
]	O
:	O

When	O
the	O
GTV	O
tumor	O
is	O
within	O
2	O
cm	O
of	O
a	O
central	O
structure	O
(	O
e.g.	O
heart	O
,	O
trachea	O
)	O
,	O
it	O
will	O
be	O
considered	O
a	O
central	O
tumor	O
.	O
In	O
such	O
a	O
scenario	O
,	O
the	O
dose	O
constraints	O
to	O
central	O
structures	O
in	O
Table	O
2	O
are	O
often	O
not	O
achievable	O
.	O
These	O
should	O
be	O
planned	O
using	O
the	O
same	O
approach	O
as	O
in	O
the	O
RTOG	O
0813	O
study	O
,	O
which	O
determined	O
the	O
safe	O
dose	O
level	O
of	O
central	O
tumors	O
for	O
a	O
5-fraction	O
SABR	O
regimen	O
.	O
In	O
such	O
an	O
approach	O
,	O
the	O
PTV	O
coverage	O
is	O
not	O
compromised	O
,	O
but	O
the	O
OAR	O
dose	O
is	O
to	O
be	O
kept	O
as	O
low	O
as	O
possible	O
.	O
This	O
applies	O
to	O
the	O
esophagus	O
,	O
heart	O
,	O
great	O
vessels	O
,	O
trachea	O
,	O
and	O
ipsilateral	O
bronchus	O
.	O
For	O
the	O
esophagus	O
,	O
great	O
vessels	O
,	O
Table	O
2	O
Recommended	O
dose	O
constraints	O
for	O
non	O
-	O
lung	O
organs	O
.	O
5-fraction	O
and	O
8-fraction	O
constraints	O
based	O
on	O
RTOG	O
0813	O
protocol	O
[	O
16	O
]	O
,	O
SABR	O
-	O
COMET	O
protocol	O
[	O
17	O
]	O
,	O
and	O
Timmerman	O
et	O
al	O
[	O
18	O
]	O
.	O
Constraints	O
for	O
other	O
fractionation	O
schemes	O
are	O
derived	O
using	O
BED	O
3	O

Number	O
of	O
Fractions	O
trachea	O
,	O
and	O
ipsilateral	O
bronchi	O
,	O
the	O
non	O
-	O
adjacent	O
wall	O
of	O
the	O
structure	O
limited	O
to	O
a	O
maximum	O
dose	O
of	O
105	O
%	O
of	O
prescription	O
dose	O
.	O
In	O
contrast	O
,	O
maximum	O
doses	O
from	O
the	O
above	O
table	O
for	O
the	O
spinal	O
cord	O
,	O
brachial	O
plexus	O
,	O
skin	O
,	O
and	O
stomach	O
are	O
NOT	O
to	O
be	O
exceeded	O
.	O

The	O
dose	O
constraints	O
to	O
the	O
lung	O
are	O
not	O
iso	O
-	O
toxic	O
,	O
meaning	O
that	O
the	O
risk	O
of	O
toxicity	O
is	O
highest	O
with	O
highest	O
dose	O
levels	O
.	O
The	O
constraints	O
below	O
based	O
are	O
those	O
used	O
for	O
5fraction	O
SABR	O
regimens	O
in	O
patients	O
without	O
ILD	O
,	O
meaning	O
that	O
with	O
a	O
higher	O
number	O
of	O
fractions	O
(	O
e.g.	O
10	O
,	O
or	O
15	O
)	O
,	O
the	O
risk	O
of	O
toxicity	O
will	O
decrease	O
.	O
The	O
pulmonary	O
constraints	O
consist	O
of	O
2	O
critical	O
volume	O
constraints	O
,	O
along	O
with	O
the	O
R100	O
,	O
R50	O
,	O
D2	O
cm	O
and	O
V20	O
(	O
volume	O
of	O
lung	O
receiving	O
at	O
least	O
20	O
Gy	O
)	O
,	O
all	O
defined	O
below	O
.	O
Critical	O
volume	O
constraint	O
for	O
both	O
lungs	O
(	O
right	O
lung	O
+	O
left	O
lung	O
)	O
:	O
a	O
total	O
critical	O
volume	O
of	O
1500	O
mL	O
receives	O
no	O
more	O
than	O
12.5	O
Gy	O
.	O
This	O
value	O
is	O
calculated	O
from	O
the	O
dose	O
-	O
volume	O
histogram	O
as	O
the	O
absolute	O
volume	O
of	O
lung	O
tissue	O
receiving	O
<	O
12.5	O
Gy	O
.	O
That	O
volume	O
must	O
be	O
at	O
least	O
1500	O
mL.	O

The	O
lung	O
constraints	O
are	O
critically	O
important	O
for	O
this	O
study	O
.	O
If	O
one	O
or	O
more	O
of	O
the	O
lung	O
constraints	O
can	O
not	O
be	O
met	O
,	O
even	O
after	O
varying	O
the	O
prescription	O
isodose	O
surface	O
percentage	O
between	O
60	O
and	O
90	O
%	O
,	O
PTV	O
coverage	O
must	O
then	O
be	O
compromised	O
.	O
Target	O
coverage	O
may	O
be	O
reduced	O
until	O
95	O
%	O
of	O
the	O
IGTV	O
is	O
receiving	O
the	O
95	O
%	O
of	O
the	O
prescription	O
dose	O
,	O
and	O
90	O
%	O
of	O
the	O
IGTV	O
is	O
receiving	O
99	O
%	O
of	O
the	O
prescription	O
dose	O
,	O
with	O
the	O
PTV	O
covered	O
as	O
well	O
as	O
possible	O
while	O
respecting	O
lung	O
constraints	O
.	O

If	O
the	O
lung	O
dose	O
constraints	O
still	O
can	O
not	O
be	O
met	O
,	O
the	O
patient	O
should	O
be	O
treated	O
with	O
a	O
10	O
or	O
15-fraction	O
regimen	O
.	O
Such	O
patients	O
treated	O
with	O
protracted	O
regimens	O
due	O
to	O
inability	O
to	O
meet	O
dose	O
constraints	O
will	O
not	O
count	O
toward	O
the	O
primary	O
analysis	O
,	O
but	O
should	O
still	O
be	O
followed	O
for	O
toxicity	O
and	O
outcomes	O
.	O
Such	O
patients	O
will	O
be	O
reported	O
as	O
a	O
separate	O
cohort	O
.	O

In	O
order	O
to	O
ensure	O
patient	O
safety	O
and	O
effective	O
treatment	O
delivery	O
,	O
a	O
robust	O
quality	O
assurance	O
protocol	O
is	O
incorporated	O
.	O
The	O
following	O
requirements	O
must	O
be	O
completed	O
for	O
each	O
patient	O
:	O

Prior	O
to	O
treatment	O
,	O
each	O
patient	O
's	O
contours	O
and	O
radiation	O
plan	O
must	O
be	O
peer	O
-	O
reviewed	O
at	O
the	O
local	O
centre	O
.	O
This	O
can	O
include	O
review	O
by	O
one	O
other	O
radiation	O
oncologist	O
,	O
or	O
discussion	O
at	O
quality	O
assurance	O
(	O
QA	O
)	O
rounds	O
.	O
OAR	O
dose	O
constraints	O
may	O
be	O
only	O
exceeded	O
with	O
approval	O
of	O
the	O
PI	O
.	O
Prior	O
to	O
plan	O
approval	O
,	O
the	O
dose	O
to	O
each	O
organ	O
at	O
risk	O
must	O
be	O
verified	O
by	O
the	O
physicist	O
or	O
treating	O
physician	O
.	O
All	O
dose	O
delivery	O
for	O
intensity	O
-	O
modulated	O
plans	O
(	O
including	O
arc	O
-	O
based	O
treatments	O
)	O
will	O
be	O
confirmed	O
before	O
treatment	O
by	O
physics	O
staff	O
.	O
Online	O
imaging	O
(	O
Cone	O
-	O
beam	O
CT	O
,	O
megavoltage	O
CT	O
or	O
orthogonal	O
KV	O
with	O
tumor	O
tracking	O
)	O
will	O
be	O
used	O
to	O
verify	O
patient	O
positioning	O
for	O
each	O
treatment	O
.	O
Ideally	O
,	O
direct	O
tumour	O
localization	O
should	O
be	O
performed	O
.	O
For	O
gated	O
SABR	O
treatments	O
,	O
direct	O
tumour	O
localization	O
will	O
be	O
performed	O
by	O
matching	O
the	O
tumour	O
position	O
with	O
the	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
defined	O
by	O
IGTV_CBCT	O
.	O
This	O
will	O
be	O
followed	O
by	O
a	O
gated	O
2dimensional	O
(	O
2D)-kV	O
in	O
the	O
anterior	O
-	O
posterior	O
plane	O
to	O
verify	O
the	O
gating	O
window	O
.	O
In	O
the	O
absence	O
of	O
direct	O
tumour	O
localization	O
,	O
reliable	O
soft	O
tissue	O
surrogates	O
are	O
recommended	O
.	O
For	O
non	O
-	O
gated	O
radiotherapy	O
,	O
it	O
is	O
expected	O
to	O
match	O
the	O
image	O
of	O
the	O
tumor	O
with	O
the	O
ROI	O
defined	O
by	O
the	O
ITV	O
.	O

Prior	O
to	O
opening	O
the	O
study	O
,	O
each	O
participating	O
research	O
centre	O
will	O
be	O
required	O
to	O
send	O
to	O
one	O
of	O
the	O
Principal	O
Investigators	O
a	O
mock	O
treatment	O
plan	O
,	O
to	O
ensure	O
that	O
the	O
treatment	O
plans	O
are	O
designed	O
in	O
compliance	O
with	O
the	O
protocol	O
.	O
The	O
principal	O
investigators	O
will	O
provide	O
pertinent	O
CT	O
datasets	O
.	O
Centers	O
that	O
have	O
previously	O
been	O
accredited	O
for	O
other	O
trials	O
(	O
e.g.	O
NRG	O
Oncology	O
,	O
CAPRI	O
,	O
LUSTRE	O
[	O
20	O
]	O
or	O
SABR	O
-	O
COMET	O
[	O
17	O
]	O
)	O
must	O
only	O
send	O
documentation	O
of	O
that	O
accreditation	O
.	O

Definitions	O
Adverse	O
Event	O
(	O
AE	O
)	O
or	O
reaction	O
,	O
as	O
per	O
definitions	O
by	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
[	O
21	O
]	O
,	O
is	O
any	O
unfavorable	O
and	O
unintended	O
sign	O
(	O
including	O
an	O
abnormal	O
laboratory	O
finding	O
)	O
,	O
symptom	O
,	O
or	O
disease	O
temporally	O
associated	O
with	O
the	O
use	O
of	O
a	O
medical	O
treatment	O
or	O
procedure	O
that	O
may	O
or	O
may	O
not	O
be	O
considered	O
related	O
to	O
the	O
medical	O
treatment	O
or	O
procedure	O
.	O
Serious	O
Adverse	O
Event	O
(	O
SAE	O
)	O
or	O
reaction	O
as	O
defined	O
in	O
the	O
International	O
Council	O
for	O
Harmonisation	O
(	O
ICH	O
)	O
Guideline	O
:	O
Clinical	O
Safety	O
Data	O
Management	O
:	O
Definitions	O
and	O
Standards	O
for	O
Expedited	O
Reporting	O
,	O
Section	O
2B	O
[	O
22	O
]	O
includes	O
any	O
untoward	O
medical	O
occurrence	O
at	O
any	O
dose	O
that	O
:	O

Results	O
in	O
death	O
Is	O
life	O
-	O
threatening	O
(	O
refers	O
to	O
an	O
event	O
in	O
which	O
the	O
patient	O
was	O
at	O
risk	O
of	O
death	O
at	O
the	O
time	O
of	O
the	O
event	O
;	O
it	O
does	O
not	O
refer	O
to	O
an	O
event	O
which	O
hypothetically	O
might	O
have	O
caused	O
death	O
if	O
it	O
were	O
more	O
severe	O
.	O
)	O
Results	O
in	O
persistent	O
or	O
significant	O
disability/	O
incapacity	O
Requires	O
in	O
-	O
patient	O
hospitalization	O
or	O
prolongation	O
of	O
existing	O
hospitalization	O
Is	O
a	O
congenital	O
anomaly	O
/	O
birth	O
defect	O
Important	O
medical	O
events	O
that	O
may	O
not	O
be	O
immediately	O
life	O
-	O
threatening	O
or	O
result	O
in	O
death	O
or	O
hospitalization	O
may	O
be	O
considered	O
a	O
serious	O
adverse	O
event	O
,	O
when	O
,	O
based	O
upon	O
medical	O
and	O
scientific	O
judgment	O
,	O
they	O
may	O
jeopardize	O
the	O
patient	O
or	O
may	O
require	O
intervention	O
to	O
prevent	O
one	O
of	O
the	O
other	O
outcomes	O
listed	O
in	O
the	O
definition	O
above	O
.	O

Unexpected	O
adverse	O
event	O
or	O
reaction	O
is	O
one	O
that	O
the	O
nature	O
and	O
severity	O
is	O
not	O
consistent	O
with	O
the	O
applicable	O
product	O
information	O
(	O
e.g.	O
,	O
Investigator	O
's	O
Brochure	O
or	O
Product	O
Monograph	O
,	O
described	O
in	O
the	O
research	O
ethics	O
board	O
(	O
REB)/institutional	O
review	O
board	O
(	O
IRB	O
)	O
approved	O
research	O
protocol	O
or	O
informed	O
consent	O
document	O
)	O
,	O
or	O
occurs	O
with	O
more	O
than	O
expected	O
frequency	O
.	O

RT	O
delivered	O
in	O
this	O
protocol	O
can	O
adversely	O
affect	O
organs	O
at	O
risk	O
,	O
most	O
notably	O
lungs	O
,	O
airway	O
,	O
esophagus	O
,	O
pulmonary	O
vessels	O
,	O
and	O
heart	O
/	O
pericardium	O
,	O
as	O
these	O
organs	O
may	O
be	O
in	O
close	O
proximity	O
to	O
the	O
intended	O
target	O
(	O
PTV	O
)	O
of	O
RT	O
.	O

Any	O
Grade	O
3	O
-	O
5	O
toxicity	O
listed	O
in	O
Table	O
4	O
will	O
automatically	O
be	O
considered	O
to	O
be	O
possibly	O
,	O
probably	O
or	O
definitely	O
related	O
to	O
treatment	O
,	O
unless	O
there	O
is	O
clear	O
evidence	O
that	O
the	O
adverse	O
event	O
is	O
unrelated	O
or	O
unlikely	O
to	O
be	O
related	O
.	O
The	O
latter	O
instance	O
may	O
occur	O
,	O
for	O
example	O
,	O
in	O
the	O
case	O
of	O
a	O
cardiac	O
event	O
in	O
a	O
patient	O
with	O
an	O
upper	O
lobe	O
tumor	O
and	O
negligible	O
heart	O
dose	O
,	O
or	O
esophageal	O
issues	O
in	O
a	O
patient	O
who	O
received	O
negligible	O
esophageal	O
dose	O
.	O
The	O
final	O
decision	O
will	O
be	O
made	O
by	O
the	O
members	O
of	O
the	O
data	O
safety	O
monitoring	O
committee	O
(	O
DSMC	O
)	O
.	O
See	O
below	O
for	O
causality	O
definitions	O
.	O

An	O
adverse	O
event	O
or	O
reaction	O
is	O
considered	O
related	O
to	O
the	O
research	O
intervention	O
(	O
i.e.	O
radiotherapy	O
)	O
if	O
there	O
is	O
a	O
reasonable	O
possibility	O
that	O
the	O
reaction	O
or	O
event	O
may	O
have	O
been	O
caused	O
by	O
the	O
research	O
intervention	O
(	O
i.e.	O
a	O
causal	O
relationship	O
between	O
the	O
reaction	O
and	O
the	O
research	O
intervention	O
can	O
not	O
be	O
ruled	O
out	O
by	O
the	O
investigator(s	O
)	O
)	O
.	O

Unrelated	O
:	O
Any	O
adverse	O
event	O
for	O
which	O
there	O
is	O
evidence	O
that	O
an	O
alternative	O
etiology	O
exists	O
or	O
for	O
which	O
no	O
timely	O
relationship	O
exists	O
to	O
the	O
administration	O
of	O
the	O
study	O
treatment	O
and	O
the	O
adverse	O
event	O
does	O
not	O
follow	O
any	O
previously	O
documented	O
pattern	O
.	O
The	O
adverse	O
event	O
,	O
after	O
careful	O
consideration	O
by	O
the	O
investigator	O
,	O
is	O
clearly	O
and	O
incontrovertibly	O
due	O
to	O
causes	O
other	O
than	O
the	O
intervention	O
.	O
Unlikely	O
:	O
Any	O
adverse	O
event	O
for	O
which	O
the	O
time	O
relationship	O
between	O
the	O
study	O
treatment	O
and	O
the	O
event	O
suggests	O
that	O
a	O
causal	O
relationship	O
is	O
unlikely	O
and/or	O
the	O
event	O
is	O
more	O
likely	O
due	O
to	O
the	O
subject	O
's	O
clinical	O
condition	O
or	O
other	O
therapies	O
concomitantly	O
administered	O
to	O
the	O
subject	O
.	O
Possible	O
:	O
Any	O
adverse	O
event	O
occurring	O
in	O
a	O
timely	O
manner	O
after	O
the	O
administration	O
of	O
the	O
study	O
treatment	O
that	O
follows	O
a	O
known	O
pattern	O
to	O
the	O
intervention	O
and	O
for	O
which	O
no	O
other	O
explanation	O
is	O
known	O
.	O
The	O
adverse	O
event	O
,	O
after	O
careful	O
consideration	O
by	O
the	O
investigator	O
,	O
is	O
considered	O
to	O
be	O
unlikely	O
related	O
but	O
can	O
not	O
be	O
ruled	O
out	O
with	O
certainty	O
.	O
Probable	O
:	O
Any	O
adverse	O
event	O
occurring	O
in	O
a	O
timely	O
manner	O
after	O
the	O
administration	O
of	O
the	O
study	O
treatment	O
that	O
follows	O
a	O
known	O
pattern	O
to	O
the	O
intervention	O
and	O
for	O
which	O
no	O
other	O
explanation	O
is	O
known	O
.	O
The	O
adverse	O
event	O
,	O
after	O
careful	O
consideration	O
by	O
the	O
investigator	O
,	O
is	O
believed	O
with	O
a	O
high	O
degree	O
of	O
certainty	O
to	O
be	O
related	O
to	O
the	O
intervention	O
.	O
Definitely	O
Related	O
:	O
Any	O
adverse	O
event	O
occurring	O
within	O
a	O
timely	O
manner	O
after	O
administration	O
of	O
the	O
study	O
treatment	O
that	O
is	O
a	O
known	O
sequela	O
of	O
the	O
intervention	O
and	O
follows	O
a	O
previously	O
documented	O
pattern	O
but	O
for	O
which	O
no	O
other	O
explanation	O
is	O
known	O
.	O
The	O
adverse	O
event	O
is	O
believed	O
by	O
the	O
investigator	O
to	O
be	O
incontrovertibly	O
related	O
to	O
the	O
intervention	O
.	O

The	O
severity	O
of	O
adverse	O
events	O
will	O
be	O
evaluated	O
using	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
CTCAE	O
)	O
v4.0	O
grading	O
scale	O
[	O
21	O
]	O
.	O

Note	O
:	O
The	O
term	O
"	O
severe	O
"	O
is	O
a	O
measure	O
of	O
intensity	O
:	O
thus	O
a	O
severe	O
adverse	O
event	O
is	O
not	O
necessarily	O
serious	O
.	O
For	O
example	O
,	O
nausea	O
of	O
several	O
hours	O
'	O
duration	O
may	O
be	O
rated	O
as	O
severe	O
,	O
but	O
may	O
not	O
be	O
clinically	O
serious	O
.	O

Any	O
grade	O
4	O
or	O
5	O
adverse	O
reaction	O
that	O
is	O
definitely	O
,	O
probably	O
,	O
or	O
possibly	O
the	O
result	O
of	O
experimental	O
treatment	O
(	O
i.e.	O
radiotherapy	O
)	O
must	O
be	O
verbally	O
reported	O
to	O
the	O
Principal	O
Investigator	O
and	O
Coordinating	O
Centre	O
within	O
24	O
h	O
of	O
discovery	O
,	O
and	O
to	O
the	O
approving	O
REB	O
if	O
necessary	O
as	O
per	O
their	O
reporting	O
guidelines	O
.	O

Local	O
and	O
non	O
-	O
local	O
SAEs	O
will	O
be	O
reported	O
to	O
the	O
applicable	O
REB	O
as	O
per	O
their	O
reporting	O
guidelines	O
.	O
All	O
serious	O
,	O
unexpected	O
adverse	O
events	O
or	O
reactions	O
regardless	O
of	O
causality	O
will	O
be	O
reported	O
within	O
7	O
days	O
of	O
discovery	O
to	O
the	O
pertinent	O
REB	O
,	O
or	O
as	O
required	O
as	O
per	O
the	O
REB	O
guidelines	O
.	O

Subjects	O
may	O
voluntarily	O
discontinue	O
participation	O
in	O
the	O
study	O
at	O
any	O
time	O
.	O
If	O
a	O
subject	O
is	O
removed	O
from	O
the	O
study	O
,	O
the	O
clinical	O
and	O
laboratory	O
evaluations	O
that	O
would	O
have	O
been	O
performed	O
at	O
the	O
end	O
of	O
the	O
study	O
should	O
be	O
obtained	O
.	O
If	O
a	O
subject	O
is	O
removed	O
because	O
of	O
an	O
adverse	O
event	O
,	O
they	O
should	O
remain	O
under	O
medical	O
observation	O
as	O
long	O
as	O
deemed	O
appropriate	O
by	O
the	O
treating	O
physician	O
.	O

Patients	O
will	O
be	O
seen	O
in	O
follow	O
-	O
up	O
as	O
per	O
Table	O
5	O
.	O
At	O
each	O
visit	O
,	O
a	O
history	O
and	O
physical	O
examination	O
will	O
be	O
conducted	O
by	O
the	O
oncologist	O
,	O
and	O
CTCAE	O
toxicities	O
recorded	O
,	O
and	O
quality	O
of	O
life	O
questionnaires	O
will	O
be	O
completed	O
.	O

CT	O
chest	O
will	O
be	O
repeated	O
at	O
3	O
,	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
,	O
then	O
annually	O
.	O
Additional	O
imaging	O
or	O
laboratory	O
investigations	O
may	O
be	O
carried	O
out	O
at	O
the	O
discretion	O
of	O
the	O
oncologist	O
.	O
Pulmonary	O
function	O
tests	O
will	O
be	O
repeated	O
at	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
.	O

It	O
is	O
expected	O
that	O
some	O
of	O
patients	O
who	O
are	O
offered	O
participation	O
in	O
this	O
trial	O
decline	O
the	O
intervention	O
,	O
and	O
thus	O
would	O
normally	O
decline	O
to	O
enter	O
the	O
study	O
.	O
Patients	O
who	O
decline	O
enrollment	O
on	O
the	O
trial	O
because	O
they	O
do	O
not	O
want	O
to	O
receive	O
radiation	O
will	O
be	O
asked	O
to	O
consent	O
to	O
follow	O
-	O
up	O
phone	O
calls	O
(	O
at	O
3-monthly	O
intervals	O
for	O
2	O
years	O
)	O
and	O
prospective	O
inclusion	O
of	O
their	O
clinical	O
data	O
collected	O
from	O
the	O
medical	O
record	O
as	O
part	O
of	O
a	O
cohort	O
of	O
patients	O
declining	O
radiotherapy	O
.	O
The	O
phone	O
calls	O
will	O
ask	O
the	O
participant	O
about	O
pulmonary	O
symptoms	O
(	O
in	O
the	O
same	O
manner	O
as	O
toxicity	O
scoring	O
is	O
done	O
in	O
patients	O
who	O
receive	O
radiotherapy	O
)	O
,	O
and	O
any	O
other	O
cancer	O
treatments	O
received	O
.	O

Survival	O
outcomes	O
:	O
OS	O
will	O
be	O
measured	O
as	O
time	O
until	O
death	O
from	O
any	O
cause	O
,	O
and	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
as	O
time	O
to	O
either	O
local	O
,	O
regional	O
or	O
distant	O
progression	O
or	O
death	O
,	O
whichever	O
occurs	O
first	O
.	O

Assessment	O
of	O
response	O
on	O
imaging	O
after	O
SABR	O
is	O
difficult	O
,	O
as	O
fibrotic	O
changes	O
in	O
the	O
lung	O
may	O
obscure	O
tumor	O
measurements	O
.	O
Nonetheless	O
,	O
the	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
1.1	O
[	O
23	O
]	O
will	O
be	O
used	O
.	O

Response	O
to	O
SBRT	O
will	O
be	O
assessed	O
by	O
a	O
central	O
review	O
process	O
,	O
where	O
the	O
PI	O
and	O
at	O
least	O
one	O
other	O
member	O
of	O
the	O
trial	O
committee	O
will	O
review	O
the	O
diagnostic	O
imaging	O
prior	O
to	O
data	O
analysis	O
to	O
determine	O
response	O
.	O
Histological	O
confirmation	O
and/or	O
PET	O
scan	O
may	O
be	O
recommended	O
to	O
assess	O
cases	O
suspicious	O
for	O
recurrence	O
.	O
Any	O
lesions	O
that	O
exhibit	O
growth	O
as	O
per	O
RECIST	O
1.1	O
criteria	O
will	O
be	O
counted	O
as	O
progression	O
,	O
unless	O
subsequent	O
scans	O
show	O
a	O
period	O
of	O
no	O
growth	O
of	O
>	O
6	O
months	O
.	O

The	O
primary	O
endpoint	O
of	O
this	O
study	O
is	O
overall	O
survival	O
in	O
patients	O
able	O
to	O
be	O
treated	O
with	O
a	O
dose	O
of	O
50	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
5	I-arm_dosage
fractions	I-arm_dosage
,	O
with	O
a	O
comparison	O
to	O
historical	O
controls	O
of	O
untreated	O
medically	O
inoperable	O
patients	O
stage	O
I	O
NSCLC	O
,	O
which	O
consistently	O
have	O
survivals	O
of	O
less	O
than	O
1	O
year	O
,	O
as	O
described	O
in	O
the	O
Background	O
section	O
.	O
Demonstration	O
in	O
this	O
study	O
that	O
median	O
OS	O
after	O
SABR	O
is	O
statistically	O
greater	O
than	O
a	O
historical	O
control	O
of	O
<	O
12	O
months	O
would	O
indicate	O
that	O
SABR	O
is	O
worthwhile	O
in	O
this	O
population	O
of	O
ILD	O
patients	O
,	O
if	O
toxicity	O
is	O
within	O
acceptable	O
limits	O
.	O

A	O
sample	O
size	O
of	O
39	O
patients	O
provides	O
>	O
80	O
%	O
power	O
to	O
detect	O
an	O
OS	O
improvement	O
of	O
>	O
20	O
%	O
at	O
1	O
year	O
,	O
compared	O
to	O
a	O
historical	O
control	O
of	O
<	O
50	O
%	O
(	O
i.e.	O
70	O
%	O
vs.	O
49	O
%	O
)	O
,	O
using	O
a	O
one	O
-	O
sample	O
,	O
one	O
sided	O
binomial	O
test	O
at	O
the	O
0.05	O
significance	O
level	O
,	O
assuming	O
10	O
%	O
dropout	O
or	O
loss	O
to	O
follow	O
-	O
up	O
before	O
one	O
year	O
.	O
All	O
cohorts	O
will	O
be	O
combined	O
for	O
this	O
primary	O
analysis	O
.	O

SABR	O
will	O
be	O
considered	O
worthwhile	O
if	O
OS	O
is	O
>	O
1	O
year	O
,	O
the	O
risk	O
of	O
grade	O
3	O
or	O
4	O
pulmonary	O
toxicity	O
is	O
<	O
35	O
%	O
,	O
and	O
the	O
risk	O
of	O
treatment	O
-	O
related	O
mortality	O
is	O
<	O
15	O
%	O
.	O

The	O
DSMC	O
will	O
meet	O
every	O
6	O
months	O
after	O
study	O
initiation	O
to	O
review	O
toxicity	O
outcomes	O
,	O
but	O
will	O
also	O
be	O
notified	O
inbetween	O
meetings	O
if	O
more	O
than	O
2	O
grade	O
5	O
treatment	O
-	O
related	O
toxicities	O
occur	O
within	O
the	O
first	O
7	O
patients	O
enrolled	O
to	O
any	O
cohort	O
,	O
or	O
for	O
any	O
subtype	O
of	O
ILD	O
regardless	O
of	O
cohort	O
.	O

The	O
dose	O
will	O
be	O
de	O
-	O
escalated	O
if	O
2	O
or	O
more	O
of	O
the	O
first	O
7	O
patients	O
in	O
a	O
specific	O
cohort	O
or	O
with	O
a	O
specific	O
ILD	O
subtype	O
experience	O
grade	O
5	O
treatment	O
-	O
related	O
toxicity	O
within	O
6	O
months	O
of	O
treatment	O
.	O
For	O
example	O
,	O
if	O
2	O
of	O
the	O
first	O
7	O
patients	O
in	O
cohort	O
III	O
experience	O
grade	O
5	O
toxicity	O
within	O
6	O
months	O
of	O
treatment	O
,	O
then	O
the	O
dose	O
will	O
be	O
de	O
-	O
escalated	O
for	O
all	O
future	O
patients	O
in	O
cohort	O
III	O
.	O
Similarly	O
,	O
if	O
2	O
of	O
the	O
first	O
7	O
patients	O
with	O
CTD	O
-	O
ILD	O
experience	O
grade	O
5	O
toxicity	O
within	O
6	O
months	O
of	O
treatment	O
,	O
then	O
the	O
dose	O
will	O
be	O
deescalated	O
for	O
all	O
future	O
patients	O
with	O
CTD	O
-	O
ILD	O
.	O

After	O
each	O
de	O
-	O
escalation	O
,	O
if	O
2	O
of	O
the	O
next	O
7	O
patients	O
in	O
that	O
cohort	O
develop	O
grade	O
5	O
toxicity	O
within	O
6	O
months	O
of	O
treatment	O
,	O
then	O
de	O
-	O
escalation	O
will	O
be	O
repeated	O
.	O
The	O
dose	O
will	O
be	O
de	O
-	O
escalated	O
to	O
50	O
Gy	O
in	O
10	O
fractions	O
,	O
then	O
45	O
Gy	O
in	O
15	O
fractions	O
,	O
using	O
the	O
same	O
dose	O
prescription	O
techniques	O
as	O
described	O
above	O
.	O
After	O
45	O
Gy	O
in	O
15	O
fractions	O
,	O
if	O
further	O
de	O
-	O
escalation	O
is	O
needed	O
then	O
that	O
cohort	O
will	O
be	O
closed	O
.	O

If	O
de	O
-	O
escalation	O
occurs	O
for	O
a	O
certain	O
cohort	O
,	O
then	O
further	O
patients	O
enrolled	O
in	O
that	O
cohort	O
will	O
be	O
treated	O
with	O
de	O
-	O
escalated	O
doses	O
but	O
will	O
not	O
count	O
towards	O
the	O
overall	O
accrual	O
goal	O
(	O
i.e.	O
there	O
will	O
be	O
39	O
patients	O
treated	O
with	O
50	O
Gy	O
in	O
5	O
fractions	O
,	O
although	O
ALL	O
patients	O
treated	O
will	O
be	O
followed	O
for	O
outcomes	O
and	O
reported	O
)	O
.	O
Final	O
results	O
will	O
be	O
stratified	O
by	O
dose	O
level	O
:	O
they	O
will	O
be	O
presented	O
for	O
all	B-arm_description
patients	I-arm_description
,	O
patients	O
treated	O
with	O
the	O
target	O
dose	O
of	O
50	B-arm_dosage
Gy	I-arm_dosage
in	I-arm_dosage
5	I-arm_dosage
fractions	I-arm_dosage
,	O
and	O
for	O
patients	B-arm_description
treated	I-arm_description
at	O
de	O
-	O
escalated	O
doses	O
.	O

The	O
protocol	O
(	O
and	O
any	O
amendments	O
)	O
,	O
the	O
informed	O
consent	O
form	O
,	O
and	O
any	O
other	O
written	O
information	O
to	O
be	O
given	O
to	O
subjects	O
has	O
been	O
reviewed	O
and	O
approved	O
by	O
the	O
Ontario	O
Cancer	O
Research	O
Ethics	O
Board	O
,	O
operating	O
in	O
accordance	O
with	O
the	O
current	O
federal	O
regulations	O
.	O
The	O
Clinical	O
Trials	O
Ontario	O
Project	O
ID	O
is	O
1488	O
.	O
Any	O
institution	O
opening	O
this	O
study	O
will	O
obtain	O
local	O
IRB/	O
REB	O
approval	O
prior	O
to	O
local	O
initiation	O
.	O
At	O
risk	O
levels	O
higher	O
than	O
30	O
%	O
,	O
which	O
are	O
thought	O
to	O
be	O
extremely	O
unlikely	O
,	O
dose	O
de	O
-	O
escalation	O
probabilities	O
rise	O
further	O
,	O
and	O
chances	O
of	O
de	O
-	O
escalation	O
within	O
the	O
first	O
few	O
patients	O
are	O
very	O
high	O

The	O
written	O
informed	O
consent	O
form	O
is	O
to	O
be	O
provided	O
to	O
potential	O
study	O
subjects	O
and	O
should	O
be	O
approved	O
by	O
the	O
local	O
IRB	O
/	O
REB	O
and	O
adhere	O
to	O
principles	O
of	O
the	O
International	O
Council	O
for	O
Harmonisation	O
Guidelines	O
for	O
Good	O
Clinical	O
Practice	O
(	O
ICH	O
GCP	O
)	O
,	O
which	O
have	O
their	O
origins	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
The	O
study	O
consent	O
form	O
can	O
be	O
found	O
in	O
Additional	O
file	O
2	O
.	O
The	O
investigator	O
is	O
responsible	O
for	O
obtaining	O
written	O
informed	O
consent	O
from	O
each	O
subject	O
,	O
or	O
if	O
the	O
subject	O
is	O
unable	O
to	O
provide	O
informed	O
consent	O
,	O
the	O
subject	O
's	O
legally	O
acceptable	O
representative	O
,	O
prior	O
to	O
beginning	O
any	O
study	O
procedures	O
and	O
treatment(s	O
)	O
.	O
The	O
investigator	O
should	O
inform	O
the	O
subject	O
,	O
or	O
the	O
subject	O
's	O
legally	O
acceptable	O
representative	O
,	O
of	O
all	O
aspects	O
of	O
the	O
study	O
,	O
including	O
the	O
potential	O
risks	O
and	O
benefits	O
involved	O
.	O
The	O
subject	O
should	O
be	O
given	O
ample	O
time	O
and	O
opportunity	O
to	O
ask	O
questions	O
prior	O
to	O
deciding	O
about	O
participating	O
in	O
the	O
study	O
and	O
be	O
informed	O
that	O
participation	O
in	O
the	O
study	O
is	O
voluntary	O
and	O
that	O
they	O
are	O
completely	O
free	O
to	O
refuse	O
to	O
enter	O
the	O
study	O
or	O
to	O
withdraw	O
from	O
it	O
at	O
any	O
time	O
,	O
for	O
any	O
reason	O
.	O
The	O
informed	O
consent	O
must	O
be	O
signed	O
and	O
dated	O
by	O
the	O
subject	O
,	O
or	O
the	O
subject	O
's	O
legally	O
acceptable	O
representative	O
,	O
and	O
by	O
the	O
person	O
who	O
conducted	O
the	O
informed	O
consent	O
discussion	O
.	O
A	O
copy	O
of	O
the	O
signed	O
and	O
dated	O
written	O
informed	O
consent	O
form	O
should	O
be	O
given	O
to	O
the	O
subject	O
or	O
the	O
subject	O
's	O
legally	O
acceptable	O
representative	O
.	O
The	O
process	O
of	O
obtaining	O
informed	O
consent	O
should	O
be	O
documented	O
in	O
the	O
patient	O
source	O
documents	O
.	O

The	O
names	O
and	O
personal	O
information	O
of	O
study	O
participants	O
will	O
be	O
held	O
in	O
strict	O
confidence	O
.	O
All	O
study	O
records	O
(	O
case	O
report	O
forms	O
,	O
safety	O
reports	O
,	O
correspondence	O
,	O
etc	O
.	O
)	O
will	O
only	O
identify	O
the	O
subject	O
by	O
initials	O
,	O
month	O
and	O
year	O
of	O
birth	O
,	O
and	O
the	O
assigned	O
study	O
identification	O
number	O
.	O
The	O
investigator	O
will	O
maintain	O
a	O
confidential	O
subject	O
identification	O
list	O
(	O
Master	O
List	O
)	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O
Access	O
to	O
confidential	O
information	O
(	O
i.e.	O
,	O
source	O
documents	O
and	O
patient	O
records	O
)	O
is	O
only	O
permitted	O
for	O
direct	O
subject	O
management	O
and	O
for	O
those	O
involved	O
in	O
monitoring	O
the	O
conduct	O
of	O
the	O
study	O
(	O
i.e.	O
,	O
Sponsors	O
,	O
contract	O
research	O
organizations	O
,	O
representatives	O
of	O
the	O
IRB/	O
REB	O
,	O
and	O
regulatory	O
agencies	O
)	O
.	O
The	O
subject	O
's	O
name	O
will	O
not	O
be	O
used	O
in	O
any	O
public	O
report	O
of	O
the	O
study	O
.	O

The	O
ASPIRE	O
-	O
MRI	O
sub	O
-	O
study	O
will	O
consist	O
of	O
separate	O
pulmonary	O
ventilation	O
and	O
perfusion	O
scanning	O
done	O
preand	O
post	O
-	O
radiotherapy	O
using	O
hyperpolarized	O
3	O
He	O
and/or	O
129	O
Xe	O
magnetic	O
resonance	O
imaging	O
at	O
the	O
Robarts	O
Research	O
Institute	O
.	O
This	O
is	O
outlined	O
in	O
Additional	O
file	O
3	O
.	O
The	O
consent	O
for	O
this	O
sub	O
-	O
study	O
is	O
in	O
Additional	O
file	O
4	O
.	O

Upon	O
completion	O
of	O
this	O
project	O
,	O
the	O
results	O
will	O
be	O
published	O
in	O
a	O
peer	O
-	O
reviewed	O
journal	O
and	O
presented	O
at	O
conferences	O
.	O
As	O
noted	O
above	O
,	O
each	O
cohort	O
may	O
be	O
reported	O
separately	O
.	O

Final	O
decisions	O
on	O
authorship	O
will	O
be	O
made	O
by	O
the	O
trial	O
steering	O
committee	O
,	O
and	O
will	O
be	O
commensurate	O
with	O
the	O
relative	O
accrual	O
of	O
each	O
center	O
and	O
the	O
amount	O
of	O
individual	O
contribution	O
,	O
including	O
study	O
design	O
,	O
patient	O
accrual	O
,	O
and	O
data	O
analysis	O
.	O
Authorship	O
on	O
all	O
publications	O
must	O
follow	O
the	O
International	O
Committee	O
of	O
Medical	O
Journal	O
Editors	O
(	O
ICMJE	O
)	O
guidelines	O
(	O
www.icjme.org	O
)	O
.	O
In	O
general	O
,	O
the	O
principal	O
investigator	O
will	O
be	O
expected	O
to	O
lead	O
all	O
publications	O
and	O
presentations	O
of	O
primary	O
endpoint	O
data	O
as	O
first	O
author	O
.	O
The	O
authorship	O
group	O
otherwise	O
consists	O
of	O
a	O
representative	O
from	O
each	O
centre	O
accruing	O
patients	O
,	O
along	O
with	O
the	O
trial	O
steering	O
committee	O
,	O
provided	O
that	O
co	O
-	O
authors	O
participate	O
in	O
the	O
authorship	O
process	O
as	O
outlined	O
by	O
ICMJE	O
.	O
Separate	O
substudies	O
or	O
reports	O
of	O
secondary	O
endpoints	O
may	O
be	O
led	O
by	O
other	O
investigators	O
within	O
the	O
group	O
.	O

Anonymized	O
imaging	O
data	O
will	O
be	O
collected	O
through	O
the	O
Quantitative	O
Imaging	O
for	O
Personalized	O
Cancer	O
Medicine	O
(	O
QIPCM	O
)	O
platform	O
(	O
qipcm.technainstitute.com	O
)	O
.	O
QIPCM	O
provides	O
centralized	O
storage	O
and	O
data	O
analysis	O
tools	O
for	O
medical	O
imaging	O
,	O
and	O
is	O
compliant	O
with	O
national	O
and	O
international	O
privacy	O
regulations	O
.	O
A	O
flowchart	O
of	O
enrollment	O
and	O
central	O
review	O
can	O
be	O
found	O
in	O
Additional	O
file	O
5	O
.	O

Scans	O
collected	O
by	O
QIPCM	O
will	O
be	O
:	O
baseline	O
CT	O
scan	O
done	O
at	O
the	O
time	O
of	O
enrollment	O
,	O
radiation	O
planning	O
scan	O
,	O
and	O
radiation	O
dose	O
distribution	O
,	O
and	O
follow	O
-	O
up	O
CTs	O
.	O
The	O
protocol	O
for	O
uploading	O
of	O
images	O
from	O
remote	O
sites	O
will	O
be	O
provided	O
in	O
a	O
separate	O
Imaging	O
Collection	O
Handbook	O
.	O